This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Unaudited standalone Q2 FY27 revenue fell 79%; net loss was Rs 8.08 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.4 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the unaudited standalone quarter ended 30 September 2026, operating revenue was Rs 16.00 lakh, down 79.2% from Rs 76.74 lakh a year earlier, and net loss was Rs 8.08 lakh versus Rs 1.41 lakh profit. Operating margin before other income, interest, depreciation and tax fell from negative 52% to negative 252%. Standalone half-year revenue was Rs 158.99 lakh and loss Rs 65.40 lakh; operating cash flow was positive. Earlier figures were recast.
Quarterly loss and 79% sales fall hurt sentiment. Only Rs 1.10 lakh cash is a concern, though positive operating cash flow and net worth offer support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.16 Cr | ₹0.77 Cr | −79.2% |
| Operating profit | −₹0.40 Cr | −₹0.40 Cr | loss widened |
| Profit after tax | −₹0.08 Cr | ₹0.01 Cr | −673.8% |
| EBITDA margin | -252.3% | -51.6% | −200.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.